Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005)

Sader, Helio S; Watters, Amy A; Fritsche, Thomas R; Jones, Ronald N

doi:10.1186/1471-2334-7-29

Table 4 Antimicrobial activity of daptomycin and selected comparators tested against European S. aureus and enterococcal isolates (2005).

From: Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005)

	MIC (μg/ml):			% category
Organism (no. tested)	50%	90%	Range	Susceptible	Resistant
S. aureus
Oxacillin-susceptible (1,946)
Daptomycin	0.25	0.5	≤0.06–1	100.0	-^a
Ciprofloxacin	0.25	0.5	≤0.03–>4	93.0	6.2
Levofloxacin	≤0.5	≤0.5	≤0.5–>4	93.9	5.9
Erythromycin	0.25	>2	≤0.06–>2	85.9	13.6
Clindamycin	≤0.25	≤0.25	≤0.5–>2	97.1	2.7
Trimethoprim/sulfamethoxazole	≤0.5	≤0.5	≤0.5–>2	99.7	0.3
Quinupristin/dalfopristin	≤0.25	0.5	≤0.25–>2	99.8	0.1
Chloramphenicol	8	8	4–>16	98.4	1.4
Rifampin	≤0.25	≤0.25	≤0.25–>2	99.4	0.5
Teicoplanin	≤2	≤2	≤2–8	100.0	0.0
Vancomycin	1	1	≤0.12–2	100.0	0.0
Linezolid	1	2	0.25–2	100.0	-
Oxacillin-resistant (800)
Daptomycin	0.25	0.5	≤0.06–1	100.0	-
Ciprofloxacin	>4	>4	0.06–>4	6.9	93.0
Levofloxacin	>4	>4	≤0.5–>4	6.8	91.1
Erythromycin	>2	>2	≤0.25–>8	24.0	74.9
Clindamycin	0.5	>2	≤0.25–>2	49.4	50.2
Trimethoprim/sulfamethoxazole	≤0.5	≤0.5	≤0.5–>2	94.1	5.9
Quinupristin/dalfopristin	0.5	1	≤0.25–>2	98.6	1.3
Chloramphenicol	8	16	≤2–>16	89.7	5.6
Rifampin	≤0.25	>2	≤0.25–>2	86.2	12.8
Teicoplanin	≤2	≤2	≤2–8	100.0	0.0
Vancomycin	1	1	0.25–2	100.0	0.0
Linezolid	1	2	0.12–2	100.0	-
Coagulase-negative staphylococci
Oxacillin-susceptible (268)
Daptomycin	0.25	0.5	≤0.06–4	99.6	-
Ciprofloxacin	0.12	4	≤0.03–>4	86.9	11.9
Levofloxacin	≤0.5	4	≤0.5–>4	87.3	10.4
Erythromycin	≤0.25	>8	≤0.25–>8	65.7	44.0
Clindamycin	≤0.25	≤0.25	≤0.25–>2	94.8	4.5
Trimethoprim/sulfamethoxazole	≤0.5	2	≤0.5–>2	91.8	8.2
Quinupristin/dalfopristin	≤0.25	≤0.25	≤0.25–1	100.0	0.0
Chloramphenicol	4	8	≤2–>16	97.4	2.6
Rifampin	≤0.25	≤0.25	≤0.25–>2	96.1	2.6
Teicoplanin	≤2	4	≤2–16	99.6	0.0
Vancomycin	1	2	≤0.12–4	100.0	0.0
Linezolid	1	1	0.12–2	100.0	-
Oxacillin-resistant (673)
Daptomycin	0.25	0.5	≤0.06–1	100.0	-
Ciprofloxacin	>4	>4	≤0.03–>4	27.8	67.5
Levofloxacin	4	>4	≤0.5–>4	28.1	62.9
Erythromycin	>2	>2	≤0.06–>2	27.2	72.7
Clindamycin	<0.25	>2	≤0.25–>2	67.0	32.5
Trimethoprim/sulfamethoxazole	2	>2	≤0.5–>2	52.6	47.4
Quinupristin/dalfopristin	≤0.25	0.5	≤0.25–>2	99.3	0.4
Chloramphenicol	4	>16	≤2–>16	86.6	13.0
Rifampin	≤0.25	>2	≤0.25–>2	85.3	13.4
Teicoplanin	≤2	8	≤2–>16	97.3	0.6
Vancomycin	1	2	≤0.12–4	100.0	0.0
Linezolid	1	1	0.25–4	100.0	-
E. faecalis
Vancomycin-susceptible (640)
Daptomycin	0.5	1	≤0.06–2	100.0	-
Ampicillin	≤1	2	≤1–16	99.4	0.6
Ciprofloxacin	1	>4	0.12–>4	64.2	34.1
Levofloxacin	1	>4	≤0.5–>4	66.1	33.0
Gentamicin (HL)^b	≤500	>1000	≤500–>1000	65.2	34.8
Streptomycin (HL)^b	≤1000	>2000	≤1000–>2000	62.0	38.0
Chloramphenicol	8	>16	≤2–>16	68.9	30.4
Quinupristin/dalfopristin	>2	>2	≤0.25–>2	0.9	93.4
Teicoplanin	≤2	≤2	≤2	100.0	0.0
Linezolid	1	2	0.5–2	100.0	0.0
Vancomycin-resistant (6)
Daptomycin	0.5	-	0.25–1	100.0	-
Ampicillin	≤1	-	2	100.0	0.0
Ciprofloxacin	>4	-	>4	0.0	100.0
Levofloxacin	>4	-	>4	0.0	100.0
Gentamicin (HL)^b	>1000	-	<500–>1000	16.7	83.3
Streptomycin (HL)^b	>2000	-	≤1000–>2000	16.7	83.3
Chloramphenicol	8	-	-	100.0	0.0
Quinupristin/dalfopristin	>2	-	>2	0.0	100.0
Teicoplanin	>16	-	>16	0.0	100.0
Linezolid	1	-	1–2	100.0	0.0
E. faecium
Vancomycin-susceptible (252)
Daptomycin	2	4	0.12–4	100.0	-
Ampicillin	>16	>16	≤1–>16	13.1	86.9
Ciprofloxacin	>4	>4	0.12–>4	7.5	78.2
Levofloxacin	>4	>4	≤0.5–>4	23.0	70.2
Gentamicin	≤500	>1000	≤500–>1000	63.1	36.9
Streptomycin	>2000	>2000	≤1000–>2000	40.1	59.9
Chloramphenicol	8	16	4–>16	83.1	7.3
Quinupristin/dalfopristin	0.5	>2	≤0.25–>2	70.2	17.9
Teicoplanin	≤2	≤2	≤2	100.0	0.0
Linezolid	1	2	0.25–2	100.0	-
Vancomycin-resistant (55)
Daptomycin	2	4	0.5–4	100.0	-
Ampicillin	>16	>16	16–>16	0.0	100.0
Ciprofloxacin	>4	>4	1–>4	3.6	92.7
Levofloxacin	>4	>4	1–>4	7.3	92.7
Gentamicin (HL)^b	>1000	>1000	≤500–>1000	47.3	52.7
Streptomycin (HL)^b	>2000	>2000	≤1000–>2000	36.4	63.6
Chloramphenicol	8	16	≤2–>16	87.1	6.5
Quinupristin/dalfopristin	1	>2	≤0.25–>2	72.7	18.2
Teicoplanin	16	>16	≤2–>16	41.8	41.8
Linezolid	1	2	0.5–2	100.0	0.0

a. - = No breakpoint has been established by CLSI [22]or US-FDA [12].
b. HL = High level resistance

Back to article page

ISSN: 1471-2334

Contact us

Submission enquiries: bmcinfectiousdiseases@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Infectious Diseases

Contact us